With people who have major psychiatric disorders being more likely to have comorbidities which could lead to worse results concerning COVID-19, researchers using a US database assessed the odds of testing positive for COVID-19, as well as mortality from COVID-19.
In a study, perceptual updating was assessed via a random dot motion perception task. Midway through the test, the motion direction changed. Study participants were then asked to report the direction.
The approval was based on data from an ongoing phase 3 trial evaluating the safety and tolerability of brexpiprazole as maintenance treatment of 194 patients aged 13 to 17 years with schizophrenia.
Researchers examined nationwide data from the Welsh Demographic Service Dataset to determine if absence and exclusion from school were associated with a record of neurodevelopmental disorder, mental disorder, and self-harm.
Individuals who were exposed to maternal diabetes in utero were at increased risk for psychiatric disorders during the first 4 decades of life.
Researchers in the United Kingdom analyzed genetic and phenotype data from the UK Biobank of 385,793 individuals aged 37 to 73 years.
Researchers assessed trends in COVID-19 vaccination, hospitalization, and mortality among individuals with schizophrenia.
A team of investigators sought to assess the impact of patients’ symptoms of tardive dyskinesia on the individuals caring for them.
Researchers conducted web-based focus groups to better understand patient preferences for medication management of a serious mental illness.
Researchers assessed adherence to treatment and hospital readmission rates in patients undergoing treatment with oral antipsychotics vs LAI paliperidone for schizophrenia.
